Lake Street raised the firm’s price target on Journey Medical (DERM) to $13 from $9 and keeps a Buy rating on the shares after the company reported Q2 revenue higher than the firm’s estimate and consensus. Though it is still early, signals from the ongoing launch of Emrosi “appear quite positive,” the analyst tells investors in a post-earnings note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: